About AnaptysBio
AnaptysBio is a company based in San Diego (United States) founded in 2005.. AnaptysBio has raised $85.23 million across 7 funding rounds from investors including Frazier Healthcare Partners, BVF Partners and BioMedPartners. The company has 136 employees as of December 31, 2024. AnaptysBio offers products and services including Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist. AnaptysBio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others.
- Headquarter San Diego, United States
- Employees 136 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Anaptysbio, Inc.
-
Annual Revenue
$91.28 M432.03as on Dec 31, 2024
-
Net Profit
$-145.23 M11.24as on Dec 31, 2024
-
EBITDA
$-112.55 M27.24as on Dec 31, 2024
-
Total Equity Funding
$85.23 M (USD)
in 7 rounds
-
Latest Funding Round
$40.77 M (USD), Series D
Jul 15, 2015
-
Investors
Frazier Healthcare Partners
& 8 more
-
Employee Count
136
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AnaptysBio
AnaptysBio is a publicly listed company on the NASDAQ with ticker symbol ANAB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AnaptysBio
AnaptysBio offers a comprehensive portfolio of products and services, including Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets PD-1+ T cells for rheumatoid arthritis and ulcerative colitis treatment
CD122 antagonist in Phase 1 trials for inflammatory conditions
BDCA2 modulator entering Phase 1 trials for autoimmune disorders
PD-1 antagonist licensed to GSK for immuno-oncology applications
Antibody licensed to GSK for potential cancer immunotherapy
Unlock access to complete
Unlock access to complete
Funding Insights of AnaptysBio
AnaptysBio has successfully raised a total of $85.23M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $40.77 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series D — $40.8M
-
First Round
First Round
(21 Jun 2007)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2015 | Amount | Series D - AnaptysBio | Valuation | BVF Partners , BioMedPartners |
|
| Oct, 2013 | Amount | Series B - AnaptysBio | Valuation |
investors |
|
| Oct, 2011 | Amount | Series B - AnaptysBio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AnaptysBio
AnaptysBio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, BVF Partners and BioMedPartners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AnaptysBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AnaptysBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Anaptysbio Comparisons
Competitors of AnaptysBio
AnaptysBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Anaptysbio
Frequently Asked Questions about AnaptysBio
When was AnaptysBio founded?
AnaptysBio was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Where is AnaptysBio located?
AnaptysBio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of AnaptysBio?
Daniel Faga is the current CEO of AnaptysBio.
Is AnaptysBio a funded company?
AnaptysBio is a funded company, having raised a total of $85.23M across 7 funding rounds to date. The company's 1st funding round was a Series B of $8.02M, raised on Jun 21, 2007.
How many employees does AnaptysBio have?
As of Dec 31, 2024, the latest employee count at AnaptysBio is 136.
What is the annual revenue of AnaptysBio?
Annual revenue of AnaptysBio is $91.28M as on Dec 31, 2024.
What does AnaptysBio do?
AnaptysBio was founded in 2005 in San Diego, United States, and operates in the biotechnology sector. Immunology therapeutics are developed by the company, focusing on immune cell modulators for autoimmune and inflammatory conditions, as well as cancer. Key programs include rosnilimab, a PD-1 agonist targeted at moderate-to-severe rheumatoid arthritis, and ANB032, a BTLA agonist for moderate-to-severe atopic dermatitis. Operations center on advancing these candidates through clinical development.
Who are the top competitors of AnaptysBio?
AnaptysBio's top competitors include Merck, Moderna and Roivant Sciences.
What products or services does AnaptysBio offer?
AnaptysBio offers Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist.
Is AnaptysBio publicly traded?
Yes, AnaptysBio is publicly traded on NASDAQ under the ticker symbol ANAB.
Who are AnaptysBio's investors?
AnaptysBio has 9 investors. Key investors include Frazier Healthcare Partners, BVF Partners, BioMedPartners, LONGWOOD INVESTMENT ADVISORS, and Novo Holdings.
What is AnaptysBio's ticker symbol?
The ticker symbol of AnaptysBio is ANAB on NASDAQ.